BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair level, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne's business model centers on providing these diagnostic services directly to healthcare providers, generating revenue through the sale of their testing services. The goal of BillionToOne is to enhance the accuracy, efficiency, and accessibility of molecular testing, driven by a commitment to growth, equality, and teamwork in making a positive impact on healthcare.